Current clinical guidelines in head and neck cancer indicate that therapeutic decisions depend not on the value of PDL-1 but on the combined positive score (CPS), which assesses the expression of PDL-1 together in tumours and immune cells. The gene discussed is CD274; the disease is neoplasm.